| Walmart Pharmacy 10-5349 | |
| 8335 E Guadalupe Rd, Mesa, Arizona 85212 | |
| (480) 357-9583 |
| Name | Walmart Pharmacy 10-5349 |
|---|---|
| Organization Name | Walmart Inc |
| Location | 8335 E Guadalupe Rd, Mesa, Arizona 85212 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (480) 357-9583 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
HHS Secretary Mike Leavitt on Monday discussed the details of an electronic prescribing incentive program scheduled to begin on Jan. 1, 2009, that will increase Medicare payments to physicians who adopt the technology, the AP/Chicago Tribune reports.
The first study identified a protein that seems to control the malignant features of brain tumor cells, suggesting a new treatment target for anti-cancer drugs. Researchers found that a little-known protein called Fra-1 was effective in controlling vascular endothelial growth factor D, a factor that promotes the growth of new blood vessels in most malignant brain tumors.
DUSA Pharmaceuticals, Inc. reported today that on the afternoon of August 5, 2010 the U.S. Food and Drug Administration notified DUSA that it has not granted Orphan Drug Designation for the use of Levulan (aminolevulinic acid HCl) Photodynamic Therapy for the prevention of cutaneous squamous cell carcinomas in patients who have a proven history of multiple localized cutaneous SCCs over a 12 month period.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for treatment resistant depression therapy, AstraZeneca/Targacept's TC-5214 will earn Decision Resources' proprietary clinical gold standard status in 2013 (following its approval that year) and through 2018.
The Center for Health Promotion and Disease Prevention at the University of North Carolina at Chapel Hill has received a five-year, $3.8 million grant from the National Heart, Lung, and Blood Institute to fund research that will address the challenge of achieving long-term weight loss among patients with obesity cared for at primary care practices.
› Verified 2 days ago
| NPI Number | 1053338277 |
| Organization Name | WALMART INC. |
| Doing Business As | WALMART PHARMACY 10-5349 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 8335 E Guadalupe Rd, Mesa, AZ 85212 |
| Phone Number | 480-357-9583 |
News Archive
HHS Secretary Mike Leavitt on Monday discussed the details of an electronic prescribing incentive program scheduled to begin on Jan. 1, 2009, that will increase Medicare payments to physicians who adopt the technology, the AP/Chicago Tribune reports.
The first study identified a protein that seems to control the malignant features of brain tumor cells, suggesting a new treatment target for anti-cancer drugs. Researchers found that a little-known protein called Fra-1 was effective in controlling vascular endothelial growth factor D, a factor that promotes the growth of new blood vessels in most malignant brain tumors.
DUSA Pharmaceuticals, Inc. reported today that on the afternoon of August 5, 2010 the U.S. Food and Drug Administration notified DUSA that it has not granted Orphan Drug Designation for the use of Levulan (aminolevulinic acid HCl) Photodynamic Therapy for the prevention of cutaneous squamous cell carcinomas in patients who have a proven history of multiple localized cutaneous SCCs over a 12 month period.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for treatment resistant depression therapy, AstraZeneca/Targacept's TC-5214 will earn Decision Resources' proprietary clinical gold standard status in 2013 (following its approval that year) and through 2018.
The Center for Health Promotion and Disease Prevention at the University of North Carolina at Chapel Hill has received a five-year, $3.8 million grant from the National Heart, Lung, and Blood Institute to fund research that will address the challenge of achieving long-term weight loss among patients with obesity cared for at primary care practices.
› Verified 2 days ago
News Archive
HHS Secretary Mike Leavitt on Monday discussed the details of an electronic prescribing incentive program scheduled to begin on Jan. 1, 2009, that will increase Medicare payments to physicians who adopt the technology, the AP/Chicago Tribune reports.
The first study identified a protein that seems to control the malignant features of brain tumor cells, suggesting a new treatment target for anti-cancer drugs. Researchers found that a little-known protein called Fra-1 was effective in controlling vascular endothelial growth factor D, a factor that promotes the growth of new blood vessels in most malignant brain tumors.
DUSA Pharmaceuticals, Inc. reported today that on the afternoon of August 5, 2010 the U.S. Food and Drug Administration notified DUSA that it has not granted Orphan Drug Designation for the use of Levulan (aminolevulinic acid HCl) Photodynamic Therapy for the prevention of cutaneous squamous cell carcinomas in patients who have a proven history of multiple localized cutaneous SCCs over a 12 month period.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for treatment resistant depression therapy, AstraZeneca/Targacept's TC-5214 will earn Decision Resources' proprietary clinical gold standard status in 2013 (following its approval that year) and through 2018.
The Center for Health Promotion and Disease Prevention at the University of North Carolina at Chapel Hill has received a five-year, $3.8 million grant from the National Heart, Lung, and Blood Institute to fund research that will address the challenge of achieving long-term weight loss among patients with obesity cared for at primary care practices.
› Verified 2 days ago
Osco Drug #0980 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1951 W Baseline Rd, Mesa, Arizona 85202 Phone: (480) 456-4850 | |
Osco Drug #1002 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 9243 E Baseline Rd, Mesa, Arizona 85209 Phone: (480) 986-4660 | |
Osco Drug #1948 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 441 N Val Vista Dr, Mesa, Arizona 85213 Phone: (480) 830-5185 | |
Osco Drug #3989 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2727 N Power Rd, Mesa, Arizona 85215 Phone: (480) 396-3838 | |
Osco Pharmacy # 958 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 325 S Power Rd, Mesa, Arizona 85206 Phone: (480) 924-8928 |